Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 209

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 209
---
 — 75,000 $2,589,750 Javier San Martin (4) Cash Bonus $262,080 — — — RSUs 01/04/2024 — — 75,000 2,589,750 Tracie Oliver (4) Cash Bonus $195,552 — — — RSUs 01/04/2024 — — 75,000 $2,589,750 (1) Amounts listed represent cash award targets for our NEOs in fiscal 2024. Actual payments were made in fiscal 2025 and the amounts are reported in the Summary Compensation Table above. There are no thresholds or maximum levels applicable under our annual cash incentive awards except with respect to Dr. Anzalone, whose target opportunity is capped at 150%. (2) These PRSUs are described above in the “Compensation Discussion and Analysis” under the heading “Equity Compensation”. (3) RSUs granted in fiscal 2024 vest in four equal annual installments beginning 1 year from the grant date. (4) Dr. San Martin and Ms. Oliver forfeited their fiscal 2024 equity awards upon their respective departures. Table of Contents 2025 PROXY STATEMENT 46

Fiscal 2024 Outstanding Equity Awards at Fiscal Year End Table The following table provides information, with respect to the NEOs, concerning the outstanding equity awards covering shares of the Company’s common stock as of September 30, 2024. Stock Awards Name Grant Date Number of Shares or Units of Stock That Have Not Vested (#) (1) Market Value of Shares or Units of Stock That Have Not Vested ($) (2) Equity Incentive Plan Awards: Number of Unearned Shares or Units of Stock That Have Not Vested (#) (3) Equity Incentive Plan Awards: Market Value of Unearned Shares or Units of Stock That Have Not Vested ($) (2) Christopher Anzalone 01/01/2020 — — 700,000 13,559,000 01/01/2021 — — 800,000 15,496,000 07/08/2022 49,761 963,871 149,282 2,891,592 12/20/2022 70,208 1,359,929 93,610 1,813,226 12/22/2023 — — 340,000 6,585,800 Kenneth Myszkowski 01/01